Gilead Sciences, Inc.
CIK: 0000882095
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- May 26, 2026ASMB
ASSEMBLY BIOSCIENCES, INC.
Award(A)Direct471.7K shares at avg. $26.50$12.5M - Feb 13, 2026XLO
Xilio Therapeutics, Inc.
Purchase(P)DirectPrefunded Warrants (right to buy)
3.7M shares at avg. $0.53- - Nov 26, 2025XLO
Xilio Therapeutics, Inc.
In-the-Money(X)DirectSeries B Warrants (right to buy)
13.3M shares- - Nov 26, 2025XLO
Xilio Therapeutics, Inc.
In-the-Money(X)DirectPrefunded Warrants (right to buy)
13.3M shares at avg. $0.75- - Aug 8, 2025ASMB
ASSEMBLY BIOSCIENCES, INC.
Purchase(P)Direct2.3M shares- - Jun 5, 2025XLO
Xilio Therapeutics, Inc.
Purchase(P)DirectSeries C Warrants (right to buy)
13.3M shares- - Jun 5, 2025XLO
Xilio Therapeutics, Inc.
Purchase(P)DirectPrefunded Warrants (right to buy)
13.3M shares- - Jun 5, 2025XLO
Xilio Therapeutics, Inc.
Purchase(P)DirectSeries A Warrants (right to buy)
13.3M shares- - Jun 5, 2025XLO
Xilio Therapeutics, Inc.
Purchase(P)DirectSeries B Warrants (right to buy)
13.3M shares- - Feb 18, 2025RCUS
Arcus Biosciences, Inc.
Purchase(P)Direct1.4M shares at avg. $11.00$15.0M - Dec 19, 2024ASMB
ASSEMBLY BIOSCIENCES, INC.
Purchase(P)Direct940.5K shares at avg. $21.37$20.1M - Dec 18, 2024XLO
Xilio Therapeutics, Inc.
Purchase(P)Direct1.8M shares at avg. $1.04$1.8M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 26, 2026 |  ASMB ASSEMBLY BIOSCIENCES, INC. | Award(A) | 471,698 | $26.50 | $12,499,997 | Direct |
| Feb 13, 2026 |  XLO Xilio Therapeutics, Inc. | Purchase(P) Prefunded Warrants (right to buy) | 3,739,000 | $0.53 | - | Direct |
| Nov 26, 2025 | XLO Xilio Therapeutics, Inc. | In-the-Money(X) Series B Warrants (right to buy) | 13,335,000 | - | - | Direct |
| Nov 26, 2025 | XLO Xilio Therapeutics, Inc. | In-the-Money(X) Prefunded Warrants (right to buy) | 13,335,000 | $0.75 | - | Direct |
| Aug 8, 2025 | ASMB ASSEMBLY BIOSCIENCES, INC. | Purchase(P) | 2,295,920 | - | - | Direct |
| Jun 5, 2025 | XLO Xilio Therapeutics, Inc. | Purchase(P) Series C Warrants (right to buy) | 13,335,000 | - | - | Direct |
| Jun 5, 2025 | XLO Xilio Therapeutics, Inc. | Purchase(P) Prefunded Warrants (right to buy) | 13,335,000 | - | - | Direct |
| Jun 5, 2025 | XLO Xilio Therapeutics, Inc. | Purchase(P) Series A Warrants (right to buy) | 13,335,000 | - | - | Direct |
| Jun 5, 2025 | XLO Xilio Therapeutics, Inc. | Purchase(P) Series B Warrants (right to buy) | 13,335,000 | - | - | Direct |
| Feb 18, 2025 |  RCUS Arcus Biosciences, Inc. | Purchase(P) | 1,363,636 | $11.00 | $14,999,996 | Direct |
| Dec 19, 2024 | ASMB ASSEMBLY BIOSCIENCES, INC. | Purchase(P) | 940,499 | $21.37 | $20,098,464 | Direct |
| Dec 18, 2024 | XLO Xilio Therapeutics, Inc. | Purchase(P) | 1,759,978 | $1.04 | $1,830,377 | Direct |
1-12 of 12 transactions
About GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC. (SEC CIK 0000882095) files insider reports with the SEC as 10% Owner of ASSEMBLY BIOSCIENCES, INC. (ASMB), 10% Owner of Xilio Therapeutics, Inc. (XLO) and 10% Owner of Arcus Biosciences, Inc. (RCUS).
Signal8 holds 8 ownership filings by GILEAD SCIENCES, INC., all Form 4s, filed between Dec 19, 2024 and May 27, 2026. Those filings report 12 transactions, from Dec 18, 2024 to May 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GILEAD SCIENCES, INC.'s filings is in FOSTER CITY, CA.
Recent filings by GILEAD SCIENCES, INC.
- May 26, 2026: Grant or award of ASMB shares (Form 4, code A).
- Feb 13, 2026: Open-market purchase of XLO derivative securities (Form 4, code P).
- Nov 26, 2025: Option exercises of XLO derivative securities (2 lines, Form 4, code X).
- Aug 8, 2025: Open-market purchase of ASMB shares (Form 4, code P).
- Jun 5, 2025: Open-market purchases of XLO derivative securities (4 lines, Form 4, code P).
Other insiders filing for ASSEMBLY BIOSCIENCES, INC. (ASMB)
- Bjorkquist Jeanette M, PFO and PAO
- Gaggar Anuj, Chief Medical Officer
- White Nicole S, Chief Manufacturing Officer
- McHutchison John G, Director
- Mahony Susan, Director
- Johnson-Pratt Lisa, Director